DAVID A. STEVENS, M.D.; PAUL L. WILLIAMS, M.D.; ALAN M. SUGAR, M.D.; ALLAN PONT, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Catanzaro and associates (1) in their article on ketoconazole and coccidioidomycosis cite three earlier studies and comment: ". . . only 20 clinical cases of coccidioidomycosis being treated with ketoconazole have been reported." The three studies cited, however, reported a total of 61 patients with coccidioidomycosis treated with ketoconazole. The number of patients studied was amplified in a subsequent report (2) and other preliminary reports were published in abstract form.
Catanzaro and associates suggest the serum half-life of ketoconazole is 5.4 hours, whereas recent pharmacokinetic studies (3) indicate a shorter time of 2.0 to 3.3 hours. Examination
STEVENS DA, WILLIAMS PL, SUGAR AM, PONT A. Ketoconazole Effects. Ann Intern Med. ;97:284–285. doi: 10.7326/0003-4819-97-2-284_3
Download citation file:
Published: Ann Intern Med. 1982;97(2):284-285.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use